Background We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. Methods In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov , NCT04501978 . Findings Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50–72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74–1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67–1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74–1·58]; BRII-196 plus BRII-198 1·00 [0·68–1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91–...

The COVID-19 pandemic has generated a wide range of socio-economic disruption, which causes devastating in numerous aspects. Our knowledge of the true health of the construction industry under the ravage of COVID-19 outbreak is largely based on very limited data. This study aims to assess the impact of pandemic on the construction industry through an investigation in Vietnam. Data were collected through 129 respondents whose online questionnaire survey completed according to their recent direct or indirect participation in delivering construction projects during the spread. The implications of COVID-19 on the construction industry were examined based on simple percentage analysis and Relative Importance Index approaches. Three principal facets of the construction industry were considered: firms' business activities, project performance, and workforce demand. The findings highlighted the multilevel, multidimensional nature of the epidemic consequences on the construction sector. Notably, the revenue and profitability, in a general sense, have decreased during the COVID-19 period, while most of the production and business costs had remained unchanged. Further, the pandemic was argued to impair construction practitioners' incomes and mental health and sabotage projects' schedule and cost.

ACTIV-3/TICO Study Group* Background: Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection.Objective: To investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared with standard care alone.

The object of study is a system of protective dams in Hanoi. In the new social and political conditions of Vietnam’s transition economy, the transformation of the riverside territories is of great importance for both the city of Hanoi and the country as a whole. A special role is given to the system of dams along the Hanga River (Red), which protect the city from floods. During the long history of construction and operation of the dams in Hanoi, many cases of their damage and destruction are known. The aim of the study is to assess the sustainability of the dams, the possible mechanisms of dam stability loss due to changes in hydrological conditions are examined. By mathematical modeling, the stability of the dam slopes and filtration strength of its base soils are calculated due to an increase in time during flooding hydraulic gradient. This task was solved in the flat setting, meanwhile, filtration modeling was carried out by the finite element method, and the estimation of the dam slopes stability was carried out based on the limit equilibrium method. The mathematical modeling allowed to estimate the dam stability from two positions: 1) change of the dam slope factor safety in time during the flood period; 2) increase of the hydraulic gradient in soils of the dam base during the flood period. The results obtained showed that the reliability of the dam depends both on the thickness of the clay layer at its base and on the duration of flooding. The factors we have identified that affect the stability of dams during flood periods can be used for predicted purposes to assess their reliability.